COMP <GO>
SHC vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Sotera Health Company (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: SHC 2
— ABBV 12
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ABBV
LAST: $18.70 (+0.27%) • MKT CAP: $5.34B
balance-sheet
1.56
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SHC VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SHC | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.50% | 70.20% | -14.70 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.10% | 29.00% | -25.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 33.5x | 33.3x | +0.20 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 2.80% | 3.47% | -0.67 | ABBV | /fcf-yield <GO> |
| Operating Margin | 8.20% | 24.60% | -16.40 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 6.70% | 6.90% | -0.20 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 8.60% | -2.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 1.56 | 5.33 | -3.77 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | SHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.2 | 65.1 | -8.90 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.15 | -0.05 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 63.7x | 113.1x | -49.40 | SHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.34B | $513.86B | -$508.52B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SHC REV | ABBV REV | SHC GROSS % | ABBV GROSS % | SHC FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.16B | $61.16B | 55.5% | 70.2% | $149.2M | $17.82B |
| FY 2024 | $1.10B | $56.33B | 54.7% | 70.0% | $45.1M | $17.83B |
| FY 2023 | $1.05B | $54.32B | — | — | -$194.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SHC // BETA 1.10
ABBV // BETA 1.15